Edition:
India

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

13.71USD
4 Dec 2020
Change (% chg)

$-0.55 (-3.86%)
Prev Close
$14.26
Open
$14.26
Day's High
$14.40
Day's Low
$13.70
Volume
222,926
Avg. Vol
440,997
52-wk High
$26.98
52-wk Low
$7.36

Latest Key Developments (Source: Significant Developments)

Adverum Biotechnologies Says Q3 Loss Per Share $0.31
Friday, 6 Nov 2020 

Nov 5 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS RECENT BUSINESS PROGRESS AND THIRD QUARTER 2020 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.31.Q3 EARNINGS PER SHARE ESTIMATE $-0.34 -- REFINITIV IBES DATA.FDA REMOVES PARTIAL CLINICAL HOLD ON ADVM-022.PLANNING TO START A PIVOTAL TRIAL FOR ADVM-022 IN WET AMD MID-2021.  Full Article

Adverum Biotechnologies Reports Q4 Loss Per Share $0.36
Tuesday, 11 Aug 2020 

Aug 10 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES ANNOUNCES POSITIVE INTERIM DATA FROM COHORTS 1-4 FROM OPTIC PHASE 1 TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD, REPORTS RECENT BUSINESS PROGRESS AND SECOND QUARTER 2020 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.36.CONTINUED ROBUST TREATMENT RESPONSE FROM BOTH HIGH AND LOW DOSES IN OPTIC PHASE 1 CLINICAL TRIAL OF ADVM-022.ADVERUM BIOTECHNOLOGIES - WELL TOLERATED ACROSS ALL COHORTS; ENCOURAGING EARLY SAFETY DATA FROM COHORT 4 IN OPTIC PHASE 1 CLINICAL TRIAL OF ADVM-022.  Full Article

Adverum Biotech Announces New Mid-Stage Trial For ADVM-022 In Diabetic Macular Edema
Friday, 29 May 2020 

May 28 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES ANNOUNCES NEW INFINITY PHASE 2 TRIAL FOR ADVM-022 IN DIABETIC MACULAR EDEMA, REPORTS RECENT BUSINESS PROGRESS AND FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.31.Q1 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.INFINITY TRIAL INITIATED FOR PATIENTS WITH DIABETIC MACULAR EDEMA.  Full Article

Adverum Biotech Reports Positive Interim Data From Cohorts 1-3 Of Optic Phase 1 Trial Of Advm-022 Intravitreal Gene Therapy For Wet AMD
Tuesday, 5 May 2020 

May 4 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS POSITIVE INTERIM DATA FROM COHORTS 1-3 OF OPTIC PHASE 1 TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD.ADVERUM BIOTECHNOLOGIES INC - ROBUST EFFICACY AND EVIDENCE OF A DOSE RESPONSE FROM SINGLE INTRAVITREAL INJECTION (IVT) OF ADVM-022.ADVERUM BIOTECHNOLOGIES INC - LONG-TERM DURABILITY BEYOND 1 YEAR FROM SINGLE IVT INJECTION OF ADVM-022 WITH ZERO RESCUE INJECTIONS IN COHORT 1.ADVERUM BIOTECHNOLOGIES INC - ENCOURAGING EARLY DATA FROM COHORT 3.ADVERUM BIOTECHNOLOGIES INC - PLANS TO INITIATE A PLANNED PHASE 1/2 CLINICAL TRIAL OF ADVM-022 FOR TREATMENT OF DIABETIC RETINOPATHY IN H2.  Full Article

Adverum Biotechnologies Reports Q4 Loss Per Share $0.29
Friday, 13 Mar 2020 

March 12 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER 2019 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.29.Q4 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.ADVERUM BIOTECHNOLOGIES - EXPECTS YEAR-END CASH POSITION, ABOUT $140.8 MILLION IN NET PROCEEDS RAISED IN FEB 2020, TO FUND OPERATIONS INTO 2022.  Full Article

Adverum Biotechnologies Announces $100 Mln Public Offering Of Common Stock
Tuesday, 11 Feb 2020 

Feb 10 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES ANNOUNCES $100 MILLION PUBLIC OFFERING OF COMMON STOCK.ADVERUM BIOTECHNOLOGIES - COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF COMMON STOCK.  Full Article

Adverum Biotechnologies Says Continued Momentum With Optic Trial For Advm-022 Intravitreal Gene Therapy In Wet AMD
Monday, 13 Jan 2020 

Jan 12 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS CONTINUED MOMENTUM WITH OPTIC TRIAL FOR ADVM-022 INTRAVITREAL GENE THERAPY IN WET AMD AND PROVIDES 2020 OUTLOOK.IND APPLICATION PLANNED FOR ADVM-022 IN DIABETIC RETINOPATHY IN 1H20; PATIENT ENROLLMENT TARGETED FOR 2H20.ADVERUM BIOTECHNOLOGIES-OPTIC PHASE 1 TRIAL PROGRESSING WITH PLANS TO COMPLETE COHORT THREE PATIENT DOSING , BEGIN ENROLLMENT IN COHORT FOUR IN 1Q20.  Full Article

Adverum Biotechnologies Reports Q3 Loss Per Share Of $0.25
Friday, 8 Nov 2019 

Nov 7 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS RECENT BUSINESS PROGRESS AND THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.25.Q3 REVENUE $300,000.Q3 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.Q3 REVENUE ESTIMATE $177,000 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $162.0 MILLION AS OF SEPTEMBER 30, 2019.  Full Article

Adverum Biotechnologies Provides Update On Optic Phase 1 Trial For Advm-022 In Wet AMD
Thursday, 16 May 2019 

May 16 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES UPDATE ON OPTIC PHASE 1 TRIAL FOR ADVM-022 IN WET AMD.ADVERUM BIOTECHNOLOGIES INC - U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS LIFTED CLINICAL HOLD ON ADVM-022.ADVERUM BIOTECHNOLOGIES - FDA LIFTED CLINICAL HOLD ON SECOND COHORT, ADVM-022 REMAINS ON PARTIAL CLINICAL HOLD FOR DOSING PATIENTS IN THIRD COHORT.ADVERUM BIOTECHNOLOGIES INC - ADVERUM WILL CONTINUE TO WORK CLOSELY WITH FDA TO RESOLVE REMAINING CMC COMMENTS..  Full Article

Adverum Biotechnologies Announces Board Changes
Friday, 3 May 2019 

May 2 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES ANNOUNCES BOARD CHANGES.ADVERUM BIOTECHNOLOGIES INC - PATRICK MACHADO APPOINTED AS BOARD CHAIR; PAUL CLEVELAND RETIRES FROM BOARD.ADVERUM BIOTECHNOLOGIES INC - INDEPENDENT DIRECTORS REKHA HEMRAJANI, JAMES SCOPA AND MARK LUPHER ADDED TO BOARD.ADVERUM BIOTECHNOLOGIES INC - BOARD CONSISTS OF NINE DIRECTORS, EIGHT OF WHOM ARE INDEPENDENT.  Full Article